A carregar...
Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US
BACKGROUND: The standard care of treatment of interferon plus ribavirin (plus protease inhibitor for genotype 1) are effective in 50 % to 70 % of patients with CHC. Several new treatments including Harvoni, Olysio + Sovaldi, Viekira Pak, Sofosbuvir-based regimens characterized with potent inhibitors...
Na minha lista:
| Publicado no: | BMC Gastroenterol |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioMed Central
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4524433/ https://ncbi.nlm.nih.gov/pubmed/26239358 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12876-015-0320-4 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|